Paradigm Biopharmaceuticals Ltd
ASX:PAR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.175
0.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Paradigm Biopharmaceuticals Ltd
Gross Margin
Paradigm Biopharmaceuticals Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | AU |
| Market Cap | 182.2m AUD |
| Gross Margin |
100%
|
| Country | FR |
| Market Cap | 6T USD |
| Gross Margin |
0%
|
| Country | US |
| Market Cap | 314.7B USD |
| Gross Margin |
67%
|
| Country | US |
| Market Cap | 147.4B USD |
| Gross Margin |
60%
|
| Country | US |
| Market Cap | 119.4B USD |
| Gross Margin |
86%
|
| Country | US |
| Market Cap | 113.8B USD |
| Gross Margin |
78%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Gross Margin |
76%
|
| Country | AU |
| Market Cap | 135.4B AUD |
| Gross Margin |
52%
|
| Country | US |
| Market Cap | 82.6B USD |
| Gross Margin |
87%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Gross Margin |
75%
|
| Country | NL |
| Market Cap | 34.3B EUR |
| Gross Margin |
89%
|
Paradigm Biopharmaceuticals Ltd
Glance View
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Paradigm Biopharmaceuticals Ltd's most recent financial statements, the company has Gross Margin of 99.9%.
You don't have any saved screeners yet
